Actively Recruiting
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-01-26
75
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
CONDITIONS
Official Title
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years, any gender
- Weight 40.0 kg or more at screening
- Diagnosed with primary membranous nephropathy by kidney biopsy
You will not qualify if you...
- Secondary membranous nephropathy
- Rapidly progressive glomerulonephritis or need for kidney transplantation
- Kidney dialysis within the previous 12 months or expected dialysis during the study
- Current or past malignant tumor
- Major surgery within the last 3 months or planned major surgery during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General hospital of eastern theater command
Nanjing, Jiangsu, China, 210002
Actively Recruiting
Research Team
Z
Zhe Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here